1. Newsroom
  2. Smug Money podcast: Healthcare investing in EM
Menu
UBP in der Presse 26.06.2020

Smug Money podcast: Healthcare investing in EM

Smug Money podcast: Healthcare investing in EM

Good With Money (19.06.2020) – UBP Head of Global Emerging Equities Mathieu Nègre joins Sustainable(ish) founder Jen Gale in a podcast to discuss healthcare investing in emerging markets.


As large parts of the world continue to battle with the coronavirus pandemic, it’s now clearer than ever that healthcare should be a major focus. As the third UN Sustainable Development Goal states, we must “ensure healthy lives and promoting well-being for all at all ages”. This was already a particularly pressing need in emerging markets long before the virus struck.

In this Smug Money podcast, UBP’s expert Mathieu Nègre shares his thoughts about healthcare investing in emerging markets with Jen Gale, founder of Sustainable(ish).

Listen to the podcast in full here:


NEGRE Mathieu_p-1.jpg
Mathieu Nègre

Head of Global Emerging Equities

Expertise

Globale Aktien

In Unternehmen mit nachhaltig besserer Mehrwertschöpfung investieren.


Auch lesenswert

UBP in der Presse 21.06.2024

How UBP bring in-house expertise to private market offerings

Asian Private Banker (28.05.2024) - With a rise in popularity of alternative investments in recent years, UBP is tapping the private market space with a mixture of specialist in-house expertise and a highly selective approach to third-party manager solutions.

UBP in der Presse 14.06.2024

UBP's Strategic Vision of Pure-Play Private Banking in Southeast Asia

Hubbis (05.06.2024) - Hubbis met with Eric Morin recently to learn more about UBP’s current momentum in Southeast Asia, the bank’s key focus areas, his strategic priorities, and his vision for the future of private banking in the region.

UBP in der Presse 12.06.2024

Strukturierte Produkte als strategische Lösung

Le Temps (10.06.2024) - Bei den strukturierten Produkten hat sich viel getan, vor allem durch die strengere Regulierung, nachdem sie von Anlegern lange mit einer gewissen Skepsis betrachtet worden waren. Diese Instrumente sind heute noch einer sehr (zu) geringen Anzahl von Kunden vorbehalten, dürften sich aber künftig wachsender Beliebtheit erfreuen. Lassen Sie mich das erklären.